Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus ORASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus ORASONE.
BREO ELLIPTA vs ORASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Orasone (prednisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
Adults: 5-60 mg orally once daily or divided twice daily; typical starting dose 5-40 mg/day. Route: oral. Frequency: once daily or every 12 hours.
None Documented
None Documented
Clinical Note
moderateDiflorasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Gatifloxacin."
Clinical Note
moderateDiflorasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Rosoxacin."
Clinical Note
moderateDiflorasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Levofloxacin."
Clinical Note
moderateDiflorasone + Trovafloxacin
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal half-life of 3-4 hours for prednisolone (active metabolite of ORASONE); clinically, duration of HPA-axis suppression is more relevant (12-36 hours) with longer effects at higher doses.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Primarily renal: ~80% as 17-keto metabolites and unchanged drug; biliary/fecal excretion accounts for <10%.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Trovafloxacin."